| abstract |
Incretin analogs with activity at each of the GIP, GLP-1 and glucagon receptors are provided. Incretin analogs have structural features that result in balanced activity and an extended duration of action at each of these receptors. Also provided are methods of treating diseases such as diabetes, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity. |